BIND Therapeutics Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Non-small Cell Lung Cancer

Published: Jul 29, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has dosed the first patient in a Phase 2 clinical trial to assess the safety and efficacy of BIND-014, a PSMA-targeted Accurin containing docetaxel, as second-line therapy in patients with non-small cell lung cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news